These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 26673822)

  • 21. Protein-tyrosine phosphatase Shp2 positively regulates macrophage oxidative burst.
    Li XJ; Goodwin CB; Nabinger SC; Richine BM; Yang Z; Hanenberg H; Ohnishi H; Matozaki T; Feng GS; Chan RJ
    J Biol Chem; 2015 Feb; 290(7):3894-909. PubMed ID: 25538234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase.
    Miura K; Wakayama Y; Tanino M; Orba Y; Sawa H; Hatakeyama M; Tanaka S; Sabe H; Mochizuki N
    Oncogene; 2013 Nov; 32(45):5292-301. PubMed ID: 23318428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small molecule 1'-acetoxychavicol acetate suppresses breast tumor metastasis by regulating the SHP-1/STAT3/MMPs signaling pathway.
    Wang J; Zhang L; Chen G; Zhang J; Li Z; Lu W; Liu M; Pang X
    Breast Cancer Res Treat; 2014 Nov; 148(2):279-89. PubMed ID: 25301089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.
    Noda S; Takahashi A; Hayashi T; Tanuma S; Hatakeyama M
    Biochem Biophys Res Commun; 2016 Jan; 469(4):1133-9. PubMed ID: 26742426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Noonan syndrome-associated D61G variant of the protein tyrosine phosphatase SHP2 prevents synaptic down-scaling.
    Lu W; Ai H; Xue F; Luan Y; Zhang B
    J Biol Chem; 2020 Jul; 295(29):10023-10031. PubMed ID: 32499374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients.
    Han T; Xiang DM; Sun W; Liu N; Sun HL; Wen W; Shen WF; Wang RY; Chen C; Wang X; Cheng Z; Li HY; Wu MC; Cong WM; Feng GS; Ding J; Wang HY
    J Hepatol; 2015 Sep; 63(3):651-60. PubMed ID: 25865556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Participation of both Gab1 and Gab2 in the activation of the ERK/MAPK pathway by epidermal growth factor.
    Meng S; Chen Z; Munoz-Antonia T; Wu J
    Biochem J; 2005 Oct; 391(Pt 1):143-51. PubMed ID: 15952937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation.
    Araki T; Mohi MG; Ismat FA; Bronson RT; Williams IR; Kutok JL; Yang W; Pao LI; Gilliland DG; Epstein JA; Neel BG
    Nat Med; 2004 Aug; 10(8):849-57. PubMed ID: 15273746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The protein tyrosine phosphatase, Shp2, is required for the complete activation of the RAS/MAPK pathway by brain-derived neurotrophic factor.
    Easton JB; Royer AR; Middlemas DS
    J Neurochem; 2006 May; 97(3):834-45. PubMed ID: 16573649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The tyrosine phosphatase SHP2 regulates focal adhesion kinase to promote EGF-induced lamellipodia persistence and cell migration.
    Hartman ZR; Schaller MD; Agazie YM
    Mol Cancer Res; 2013 Jun; 11(6):651-64. PubMed ID: 23512980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.
    Aceto N; Sausgruber N; Brinkhaus H; Gaidatzis D; Martiny-Baron G; Mazzarol G; Confalonieri S; Quarto M; Hu G; Balwierz PJ; Pachkov M; Elledge SJ; van Nimwegen E; Stadler MB; Bentires-Alj M
    Nat Med; 2012 Mar; 18(4):529-37. PubMed ID: 22388088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
    Matalkah F; Martin E; Zhao H; Agazie YM
    Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells.
    Fernandis AZ; Prasad A; Band H; Klösel R; Ganju RK
    Oncogene; 2004 Jan; 23(1):157-67. PubMed ID: 14712221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A suggested role for mitochondria in Noonan syndrome.
    Lee I; Pecinova A; Pecina P; Neel BG; Araki T; Kucherlapati R; Roberts AE; Hüttemann M
    Biochim Biophys Acta; 2010 Feb; 1802(2):275-83. PubMed ID: 19835954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies.
    Liu X; Zheng H; Li X; Wang S; Meyerson HJ; Yang W; Neel BG; Qu CK
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):984-9. PubMed ID: 26755576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.
    Xie J; Si X; Gu S; Wang M; Shen J; Li H; Shen J; Li D; Fang Y; Liu C; Zhu J
    J Med Chem; 2017 Dec; 60(24):10205-10219. PubMed ID: 29155585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
    Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
    Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGFR-activated Src family kinases maintain GAB1-SHP2 complexes distal from EGFR.
    Furcht CM; Buonato JM; Lazzara MJ
    Sci Signal; 2015 May; 8(376):ra46. PubMed ID: 25969544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Noonan syndrome-associated SHP2 mutation differentially modulates the expression of postsynaptic receptors according to developmental maturation.
    Oh JY; Rhee S; Silva AJ; Lee YS; Kim HK
    Neurosci Lett; 2017 May; 649():41-47. PubMed ID: 28366775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
    Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
    PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.